XML 70 R61.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Reporting - Schdule of Operating Financial Result (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Total Revenue $ 72,788   $ 37,958   $ 137,652 $ 57,753
Less: Significant and other segment expenses            
Cost of Product Sales 3,208   1,279   5,841 2,164
Research and development 68,036   62,227   126,881 123,863
Royalty interest expense 12,119   7,854   23,965 15,903
Convertible note interest expense 555   0   555 0
Segment net loss (49,363) $ (42,673) (71,847) $ (84,846) (92,036) (156,693)
Biopharmaceutical Cancer Therapeutics Member            
Segment Reporting [Line Items]            
Total Revenue 72,788   37,958   137,652 57,753
Less: Significant and other segment expenses            
Cost of Product Sales 3,208   1,279   5,841 2,164
Other R&D programs 1,043   1,826   1,205 2,747
Personnel cost and other expenses 18,308   18,997   37,606 35,528
Commercial related expenses 9,869   9,914   17,590 20,739
Personnel cost and other expenses 16,298   19,307   32,999 38,389
Other SG&A expenses 5,868   4,993   11,008 9,405
Stock-based compensation 14,014   13,787   26,067 24,167
Royalty interest expense 12,119   7,854   23,965 15,903
Convertible note interest expense 555   0   555 0
Interest expense (income), net (3,744)   (5,946)   (7,305) (13,127)
Other expense, net 438   586   624 807
Segment net loss (49,363)   (71,847)   (92,036) (156,693)
Biopharmaceutical Cancer Therapeutics Member | Revumenib-Related Costs Member            
Less: Significant and other segment expenses            
Research and development 35,493   28,155   61,218 48,960
Biopharmaceutical Cancer Therapeutics Member | Axatilimab-Related Costs Member            
Less: Significant and other segment expenses            
Research and development $ 8,682   $ 9,053   $ 18,315 $ 28,764